Molecular Pathogenesis and Systemic Therapies for Hepatocellular Carcinoma

Overview

Journal Nat Cancer

Specialty Oncology

Date 2022 Apr 28

PMID 35484418

Authors

Josep M Llovet

Roser Pinyol

Robin K Kelley

Anthony El-Khoueiry

Helen L Reeves

Xin Wei Wang

Gregory J Gores

Augusto Villanueva

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.

Citing Articles

LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Suoangbaji T, Long R, Ng I, Mak L, Ho D Cancers (Basel). 2025; 17(5).

PMID: 40075736 PMC: 11898674. DOI: 10.3390/cancers17050890.

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.

Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.

PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.

Development of a prognostic model for hepatocellular carcinoma based on microvascular invasion characteristic genes by spatial transcriptomics sequencing.

Mu X, Pan L, Wang X, Liu C, Li Y, Cai Y Front Immunol. 2025; 16:1529569.

PMID: 40051627 PMC: 11882567. DOI: 10.3389/fimmu.2025.1529569.

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma.

Zhang Y, Ma Y, Ma E, Chen X, Zhang Y, Yin B Cancer Drug Resist. 2025; 8:10.

PMID: 40051497 PMC: 11883234. DOI: 10.20517/cdr.2024.165.

FVTF inhibits hepatocellular carcinoma stem properties via targeting DNMT1/miR-34a-5p/FoxM1 axis.

Cao X, Peng J, Qiu Y, Zhu W, Cao J, Zou H Chin Med. 2025; 20(1):32.

PMID: 40050970 PMC: 11884036. DOI: 10.1186/s13020-025-01084-3.

References

Kadalayil L, Benini R, Pallan L, OBeirne J, Marelli L, Yu D . A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013; 24(10):2565-2570. PMC: 4023407. DOI: 10.1093/annonc/mdt247. View

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

Llovet J, Decaens T, Raoul J, Boucher E, Kudo M, Chang C . Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013; 31(28):3509-16. DOI: 10.1200/JCO.2012.47.3009. View

Llovet J, Hernandez-Gea V . Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20(8):2072-9. DOI: 10.1158/1078-0432.CCR-13-0547. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

Sun T, Annunziato S, Bergling S, Sheng C, Orsini V, Forcella P . ZNRF3 and RNF43 cooperate to safeguard metabolic liver zonation and hepatocyte proliferation. Cell Stem Cell. 2021; 28(10):1822-1837.e10. DOI: 10.1016/j.stem.2021.05.013. View

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

10.

Rochigneux P, Chanez B, de Rauglaudre B, Mitry E, Chabannon C, Gilabert M . Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers (Basel). 2021; 13(2). PMC: 7828372. DOI: 10.3390/cancers13020271. View

11.

Um T, Kim H, Oh B, Kim M, Kim K, Jung G . Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 2010; 54(5):939-47. DOI: 10.1016/j.jhep.2010.08.021. View

12.

Meunier L, Hirsch T, Caruso S, Imbeaud S, Bayard Q, Roehrig A . DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology. 2021; 74(2):816-834. DOI: 10.1002/hep.31796. View

13.

Pinyol R, Torrecilla S, Wang H, Montironi C, Pique-Gili M, Torres-Martin M . Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2021; 75(4):865-878. DOI: 10.1016/j.jhep.2021.04.049. View

14.

Ramachandran P, Matchett K, Dobie R, Wilson-Kanamori J, Henderson N . Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. Nat Rev Gastroenterol Hepatol. 2020; 17(8):457-472. DOI: 10.1038/s41575-020-0304-x. View

15.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

16.

Singal A, Hoshida Y, Pinato D, Marrero J, Nault J, Paradis V . International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology. 2021; 160(7):2572-2584. PMC: 8169638. DOI: 10.1053/j.gastro.2021.01.233. View

17.

Guo M, Zhang H, Zheng J, Liu Y . Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020; 11(8):2008-2021. PMC: 7052944. DOI: 10.7150/jca.39972. View

18.

Kim H, Bang Y, Lee M, Kim J, Kim J, Chon H . Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020; 40(10):2544-2552. DOI: 10.1111/liv.14573. View

19.

Vincenzi B, Di Maio M, Silletta M, DOnofrio L, Spoto C, Piccirillo M . Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One. 2015; 10(7):e0133488. PMC: 4521926. DOI: 10.1371/journal.pone.0133488. View

20.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View